Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900146 · ClinicalTrials.gov registry record · Phase 2
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
A Phase 2 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 556
- Enrollment target
NCT00900146 is a Phase 2 study that was terminated before completion, run by Novartis. The registered enrollment target is 556 participants.
The verdict
NCT00900146, a Phase 2 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 556 participants
- Enrollment target
Study Summary
This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of patients with Type 2 diabetes mellitus (T2DM) already treated on maximum dose metformin.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Canakinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 556 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00900146
The ClinicalTrials.gov registry entry for NCT00900146 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 556 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00900146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00900146 about?
NCT00900146 is a clinical study titled "Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients". This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of patients with Type 2 diabetes mellitus (T2DM) already treated on maxim...
What is the current status of trial NCT00900146?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 556 participants. The study started on 2009-04. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00900146?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Canakinumab (DRUG).
Who is sponsoring clinical trial NCT00900146?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.